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Proliferation dynamics of acute myeloid leukaemia
and haematopoietic progenitors competing for
bone marrow space
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Leukaemia progressively invades bone marrow (BM), outcompeting healthy haematopoiesis
by mechanisms that are not fully understood. Combining cell number measurements with a
short-timescale dual pulse labelling method, we simultaneously determine the proliferation
dynamics of primitive haematopoietic compartments and acute myeloid leukaemia (AML).
We observe an unchanging proportion of AML cells entering S phase per hour throughout
disease progression, with substantial BM egress at high levels of infiltration. For healthy
haematopoiesis, we find haematopoietic stem cells (HSCs) make a significant contribution to
cell production, but we phenotypically identify a quiescent subpopulation with enhanced
engraftment ability. During AML progression, we observe that multipotent progenitors
maintain a constant proportion entering S phase per hour, despite a dramatic decrease in
the overall population size. Primitive populations are lost from BM with kinetics that are
consistent with ousting irrespective of cell cycle state, with the exception of the quiescent
HSC subpopulation, which is more resistant to elimination.
DOI: 10.1038/s41467-017-02376-5 OPEN
1 Department of Life Sciences, Sir Alexander Fleming Building Imperial College London London, SW7 2AZ, UK. 2 Hamilton Institute Maynooth University
Maynooth, Co Kildare W23 WK26, Ireland. 3 The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC 3052, Australia. 4 Department of
Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia. 5 The Francis Crick Institute, 1 Midland Road, London, NW1A 1AT, UK.
O. Akinduro and T.S. Weber contributed equally to this work. Correspondence and requests for materials should be addressed to
K.R.D. (email: ken.duffy@mu.ie) or to C.L.C. (email: c.lo-celso@imperial.ac.uk)
NATURE COMMUNICATIONS |  (2018) 9:519 |DOI: 10.1038/s41467-017-02376-5 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Haematopoietic cells generate a turnover of billions ofblood cells every day. The population-level paradigm forthis system is the haematopoietic tree, a hierarchical
commitment structure describing progressive amplification and
differentiation with rare haematopoietic stem cells (HSCs) at its
top1. These self-renewing, multipotent cells give rise to a cascade
of increasingly lineage-restricted progenitors that are not self-
renewing. Steady-state blood cell production heavily relies on
proliferation of intermediate progenitor cells, while more primi-
tive populations such as HSCs are known to be relatively quies-
cent. Consequently, the mechanisms regulating HSC quiescence
have been studied in great detail, and dormant HSC subpopula-
tions have been identified2–5. In contrast, proliferative HSCs and
downstream progenitors have been less well studied, despite their
crucial role in maintaining steady-state haematopoiesis and
regeneration following injury6. Understanding the kinetics of
these cells holds vital clues about the regulation of these pro-
cesses. It has, for example, been determined that HSCs become
more proliferative in response to certain stresses, including
infection7–10, but the fate of proliferative stem and progenitor
cells under leukaemic stress is unknown.
Leukaemia is a form of cancer that originates from blood
lineage cells. As leukaemia invades bone marrow (BM), haema-
topoiesis decreases to such an extent that patients typically pre-
sent with symptoms such as anaemia, excessive bleeding or
recurrent infections. How leukaemia outcompetes healthy hae-
matopoiesis is only partially understood. It has been established
that residual HSCs, both in murine leukaemia models and
patients, are still functional in transplantation settings11–13.
Furthermore, leukaemia-induced changes in BM stroma have
been identified at advanced stages of disease14–17. Exactly how
leukaemia leads to impaired haematopoiesis is yet to be deter-
mined, but potential explanations include: (I) a block in differ-
entiation of haematopoietic progenitors13; (II) a reduction in
stem and progenitor cell production rates12; and (III) an increase
in apoptosis or emigration. We used the MLL-AF9 mouse model
of acute myeloid leukaemia (AML) to better understand the
contribution of each of these processes. (I) We determined
absolute cell numbers of AML and haematopoietic stem and
progenitor cells (HSPCs). (II) We quantified the numbers of AML
cells and HSPCs entering S phase per hour. (III) We measured
the proportion of apoptotic cells, and the appearance of healthy
and malignant cells in blood and spleen.
Measurement of absolute numbers of healthy and apoptotic
cells can be obtained by well-established flow cytometry
protocols18, 19. In contrast, quantification of cell production rates
remains challenging. The proliferative behaviour of HSPCs has
been studied in vivo through snapshot analysis of cell distribution
across cell cycle stages20, 21, uptake of 5-bromo-9-deoxyuridine
(BrdU) or other nucleoside analogues over hours or days22, 23, and
through label retention or dilution2, 3, 24. However, cell production
rates are not inferable from these methods. Dual pulse-chase
nucleoside analogue labelling, pioneered by Wimber and Quas-
tler25, identifies all cells that have entered into S phase in a given
timeframe. We applied it to understand the cellular dynamics
underlying AML growth and parallel loss of healthy haemato-
poiesis. We focused on HSPC populations phenotypically defined
by SLAM gating2, 3, 26–29 and studied the following populations:
lineage−/lowc-Kit+Sca-1+ (LKS) CD150+CD48−/low, LKS CD150−
CD48−/low and LKS CD48+ cells. For brevity, consistent with
multiple recent publications30–34, we use the terminology HSCs,
short term HSCs (ST-HSCs) and multipotent progenitors (MPPs),
respectively, for each of these phenotypes. In addition, we mea-
sured absolute cell numbers, and proportions of apoptotic cells.
We found that a constant proportion of AML cells entered S
phase per hour, and only AML cells in peripheral blood (PB) were
less proliferative. We found that in steady-state conditions, MPPs
amplify cell numbers more significantly than ST-HSCs or HSCs.
The MPP compartment size is, however, comparable with the
number of new cells produced every 2 weeks by HSCs and ST-
HSCs. We identified that HSCs with the lowest levels of cell
surface CD48 expression as the least proliferative in steady-state,
and the best engrafters in transplantation. Contrary to expecta-
tion, as leukaemia invaded the BM and HSPC compartments
became depleted, the fraction of MPPs entering S phase per hour
remained largely unchanged. The loss of healthy cells was con-
sistent with neutral ousting from BM by AML irrespective of cell
type, with the exception of HSCs with the lowest levels of CD48,
which proved more resistant to elimination.
Results
AML and HSPC cell counts during AML progression. GFP+
MLL-AF9-induced blast cells from primary leukaemic mice35
were injected into non-irradiated secondary recipient mice, which
consistently developed high leukaemia burden within 3.5 weeks
from injection (Fig. 1a). This approach allowed us to avoid
irradiation-related injury of the haematopoietic system. To obtain
detailed information on cell number dynamics, at days 12, 15, 18,
21 and 24, BM and spleen were harvested, and AML and non-
malignant mononuclear cells (MNC, excluding red blood cells)
counts were determined.
AML cell numbers in BM increased exponentially from day 12
to day 18, followed by a period of slower growth in cell numbers
over days 21 and 24, which constitute the final stages of the
disease (Fig. 1b, left). At day 24, this resulted in 4.87 × 107
(±4.6 × 106 s.e.m) AML cells in BM contained within two tibias,
two femurs and two ileac bones of each mouse analysed. BM
MNC counts in the same bones started at 1.08 × 108± 3.93 × 106
cells and remained largely unchanged at homoeostatic levels until
day 21. Over days 21–24, as the growth in AML cell numbers was
tailing off, MNC counts dropped to approximately a tenth of their
starting number (Fig. 1b, right).
During disease progression, the spleen weights were measured,
revealing significant enlargement (Fig. 1c) as a result of
colonisation by leukaemia cells (Supplementary Fig. 1) combined
with extramedullary haematopoiesis. Spleen weight dynamics
contrasted with the growth of AML cell numbers in BM, as there
was some expansion between days 12 and 18, but a dramatic
increase over days 21 and 24, coincident with slower growth of
AML cell counts in BM (Supplementary Fig. 1).
Within the MNC compartment, we analysed the cell number
dynamics of significant phenotypically defined stem and
progenitor cell populations, HSCs (LKS CD150+CD48−/low),
ST-HSCs (LKS CD150-CD48−/low) and MPPs (LKS CD48+)
(Supplementary Fig. 2). These cell populations sit at the top of the
haematopoietic tree where its topology is typically described as
linear, with HSCs giving rise to ST-HSCs, and these in turn
to MPPs (Fig. 1d)26, 29, 30, 32. HSCs have been further subdivided
based on expression of CD34 and functionally by retention of
genetic or chemical labels2, 3, 31, 36. Lineage tracing experiments
have so far considered LKS CD150+ CD48−/low as a single
population6, 30, 32. LKS CD48+ cells have been further subdivided
based on expression of Flk2, CD48 and CD150 to enrich for
granulo-monocyte, erythro-megakaryocyte or lymphoid lineage
biased MPPs26, 29, 31.
Downstream of LKS CD48+ cells are populations with a
hierarchical relationship that is not yet fully characterised37–41.
The dynamics of HSC, ST-HSC and MPP cell numbers mimicked
those of MNCs as a whole, remaining largely unchanged until
growth in AML cell numbers decreased, at which point they
dropped dramatically. Interestingly, we detected significant
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differences between the cell populations analysed, with ST-HSCs
already significantly reduced by day 21, while HSCs and MPPs
were more variable at that time (Fig. 1e).
These data were consistent with multiple hypotheses. For
example, the AML cell number data were compatible with a
decrease in AML proliferation or increase in apoptosis from day
21. They were also compatible, however, with a model where
AML proliferation continues unabated, but a lack of space in BM
results in cells being displaced into PB. Similarly, HSPC numbers
could decrease due to an overall decrease, or even shut down, of
healthy cell proliferation and/or increased death. Alternatively,
healthy cells could be eliminated by leukaemia through active
mechanisms, such as “winning” competition for space. In order to
distinguish between these possibilities, we reasoned that we
required additional information on proliferation dynamics.
Identification of cells entering S phase. Cells undergoing S phase
in the presence of BrdU incorporate it into their DNA. Con-
tinuous delivery of BrdU results in a consistent pattern of label-
ling22 (solid line in Fig. 2a), where the number of BrdU+ cells
measured is the sum of all cells that were in S phase at the time of
initial delivery plus a decreasing proportion of additional cells
over time as BrdU− cells start DNA synthesis and BrdU+ cells
cycle further. Analysis of cells harvested shortly after a pulse of
BrdU identifies all cells in S phase in that window, but in order to
convert that number into a proportion of cells entering S phase
per hour, one would need to divide it by the duration of S phase,
which is unknown and variable. The proportion of cells entering
S phase per unit time is the derivative at the origin of the curve
depicting the proportion of cells labelled under continuous BrdU
administration (Fig. 2a, red dashed line). In the absence of cell
cycle arrest and endocycling, this serves as a proxy for the fraction
of the population that is proliferating at the time of measurement.
This derivative cannot be deduced from a single time-point
measurement with a single label-uptake system as one must
measure the offset at time zero as well as a second measurement
shortly after label administration.
To overcome these limitations, we further developed a short-
timeframe, dual pulse label system that was previously estab-
lished, verified and used in multiple studies, primarily focused on
immune cell proliferation42–47. It is based on combining BrdU
with another thymidine analogue, 5-ethynyl-2′-deoxyuridine
(EdU). An initial intravenous EdU pulse was followed 2 h later
by intravenous administration of BrdU, and 30 min later cells
were harvested and analysed (Fig. 2b). All cells that were in S
phase at the time of the initial EdU pulse became EdU+ (blue
cells, Fig. 2c, left and middle), while cells that were in S phase
during both pulses became EdU+BrdU+ double positive (purple
cells, Fig. 2c). Cells that entered S phase in the 2 h between the
initial EdU pulse and the BrdU pulse were negative for the EdU
label but positive for BrdU label (EdU−BrdU+, orange cells in
Fig. 2c). With this method, one obtains a measurement of the
proportion of cells in a population entering S phase in a given 2-h
time window. By multiplying the proportion of EdU−BrdU+ cells
by the overall number of cells, the number of cells in that
population that entered S phase in the 2-h window can be
calculated.
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Fig. 1 Population dynamics of healthy and malignant haematopoietic cells as leukaemia progresses. a Cohorts of mice were injected i.v. with 100,000 MLL-
AF9 AML blasts at day 0. Control and diseased mice were culled at days 12, 15, 18, 21 and 24, for flow cytometry analysis of BM cells (tibeas, femurs and
ileac crest bones). b Between days 18 and 24, as AML cell numbers grow in the BM (p= 0.003, Welch two-sample t-test), mononuclear cell counts
decrease significantly (p= 5.43e−04, Welch two-sample t-test). c Spleen weights increase following AML cells injection, slowly at first and significantly by
day 21 (p= 0.016, Welch two-sample t-test) and day 24 (p= 0.001, Welch two-sample t-test). d At the apex of the haematopoietic cascade are HSCs, ST-
HSCs and MPPs. Cells in each population proliferate (circular arrows) and differentiate into the downstream population (straight arrows). e Quantification
of HSC (LKS CD150+CD48−/low), ST-HSC (LKS CD150-CD48−/low) and MPP (LKS CD48+) cell numbers as disease progresses. A significant reduction in
population size was observed between days 18 and 24 in all populations (p= 0.04 HSCs, p= 0.03 ST-HSCs and p= 0.046 MPPs, Welch two-sample t-
test); n= 15 control in total and 3 leukaemic mice per time point analysed, apart for c where 4–6 spleens/time point are shown. Results from one cohort
shown, with equivalent results obtained from two other independent experiments
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The interval between the EdU and BrdU pulses was chosen
based on two competing factors. For accurate inference, it had to
be long enough to capture a sufficiently large number of cells
entering S phase. However, it also had to be short enough to ensure
that, in the interval between the pulses, cells could neither pass
through S phase during the interval without label uptake, as that
would result in an EdU−BrdU− cell in lieu of an EdU−BrdU+ cell,
nor take up the EdU label, transit through G2/M/G1, and re-enter
S phase picking up the BrdU label, as that would result in two EdU
+BrdU+ cells instead of one EdU+BrdU− cell. In vitro time lapse
microscopy of activated fluorescence ubiquitination cell cycle
indicator (FUCCI) lymphocytes indicated a lower bound on G1 of
approximately 2 h and that S/G2/M is typically greater than 4 h48,
guiding our consideration to intervals of 2 h or less.
To confirm the method’s accuracy, we analysed HSPC
populations of mice that were pulsed with EdU, and received
BrdU 1 or 2 h later. As expected, increasing the gap from 1 to 2 h
led to a 2-fold increase in the proportions of EdU−BrdU+ cells for
all HSCs, ST-HSCs and MPPs populations (Fig. 2d). We chose a
2-hour labelling period as it increased the number of BrdU single
positive labelled cells, and therefore provided increased accuracy
for more quiescent populations.
We confirmed that we could detect differences in the rate of S
phase entry by examining the mice treated with the immune-
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Fig. 2 EdU and BrdU dual pulse allows measurement of rate of entry into S phase of haematopoietic cell populations. a Assuming a constant proportion of
cells are in S phase (black dotted line), continuous administration of BrdU alone leads to progressive accumulation of the thymidine analogue in a growing
proportion of the cell population (black line). The rate of entry in S phase at the time of the first administration is the derivative at the origin of the curve
(dashed red line) and cannot be calculated from a single mouse. b Experimental setup: mice were administered EdU first, then BrdU 2 h later, and 30min
later were culled, and haematopoietic cells were analysed by flow cytometry. c Diagram representing the dynamics of cell labelling. EdU first labels all the
cells in S phase (dark blue). In the 2-h gap, some of these cells progress through G2 and mitosis, while others continue to synthetise DNA (dark blue). In
parallel, some unlabelled cells enter S phase (empty circles). BrdU again labels all the cells in S phase, with the following results: cells that entered S phase
during the 2-h gap are BrdU single positive (orange circles), cells that were in S phase during both pulses are double positive (purple circles), and cells that
terminated S phase prior to the BrdU pulse are EdU single positive (blue circles). d Validation of the dual-pulse method. A 2-h gap between pulses results
in a 2-fold increase in the number of labelled cells compared to a 1-h pulse (shown is average ± s.e.m; p= 0.84 HSC, p= 0.99 ST-HSC, p= 0.61 MPP,
Welch two-sample t-test; n= 3 mice with 1 h gap, and n= 3 mice with a 2 h gap). e Dual-pulse method can identify the changes in proliferation rate of cell
populations. Mice were administered poly I:C prior to EdU and BrdU, 24 h prior to culling, and the proportions of S phase HSCs, ST-HSCs and MPPs were
compared to those of control mice (average ± s.e.m shown; p= 0.04 HSC, p= 0.01 ST-HSC, p= 0.07 MPP, Welch two-sample t-test; n= 3 control and
n= 3 poly I:C treated mice)
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stimulant polyinosinic:polycytidylic acid (poly I:C)8. As antici-
pated, 24 h after poly I:C administration, primitive haematopoie-
tic cells were recruited in the cell cycle, and we detected a 5.4±
1.03, 4.9± 0.48 and 1.5± 0.16-fold increase in the proportion of
EdU−BrdU+ HSCs, ST-HSCs, and MPPs, respectively (Fig. 2 e).
AML proliferation scales linearly with the population size.
Having established the dual-pulse method, we measured the
number of AML cells entering S phase per hour. At every time
point, for each mouse we determined both total cell numbers and
the number of cells entering S phase in a 2-h window in the BM
and spleen. That data established that the number of AML cells
entering S phase per hour in both BM (Fig. 3a) and spleen
(Fig. 3b) was a fixed fraction of the total number of AML cells.
This linear relationship indicated that AML cells maintained
consistent proliferation even when cell numbers in BM were no
longer growing exponentially (Fig. 1b, days 21–24).
As AML cells undergo exponential growth in the BM between
days 12 and 18 (Fig. 1b), and between days 18 and 24 in the
spleen (Supplementary Fig. 1), this afforded us an additional
opportunity to confirm the dual label method’s accuracy. For a
cell population undergoing negligible cell death and growing
exponentially, exponential regression enables estimation of the
proportion of the population proliferating per unit time. While
no method exists to quantitatively determine the number of cells
dying per hour in vivo, analysis of apoptotic AML cells by
Annexin V and DAPI staining confirmed that these undergo little
death (Fig. 3c). Thus, exponential regression from total AML cell
numbers provided an estimate that ~3% AML cells enter S phase
per hour in both BM and spleen during the exponential growth
phase. The dual label measurement provided the same estimate
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Fig. 3 Proliferation and BM egression dynamics of AML cells. Number of AML cells entering S phase per hour in BM (a) and spleen (b) are plotted against
absolute numbers of AML cells in tibea, femur and ileac crest bones of mice at multiple time points following injection of AML blasts (colour and shape
coded). Black lines are linear regression of the data, with confidence intervals in grey. c Very small proportions of apoptotic cells (DAPI and/or Annexin V
positive) are detectable within the AML cell population throughout disease progression (average ± s.e.m shown; days 15 and 24, p= 0.07, Welch two-
sample t-test; n= 3 mice at each time point). d Proportion of AML cells entering S phase per hour estimated for BM (grey bars) and spleen (white bars)
using dual-pulse method (left) and exponential regression from data presented in Fig. 1b and Supplementary Fig. 1 (average ± s.e.m; BM vs. spleen EdU−
BrdU+ estimates p= 0.8208, Welch two-sample t-test; n= 9 mice). e The proportion of AML cells in PB (RBC lysed) increases slowly following injection of
blasts, and dramatically by the late stages of the disease (average ± s.e.m; n= 3 mice per time point). f Comparison of estimated number of AML cells
exiting BM between days 18 and 24, and measured increase in MNCs in blood during those days (average ± bootstrap std. deviation shown for estimate,
average ± s.e.m shown for measured values; estimate, n= 6 samples based on measurements presented in Figs. 1b and 3a; measured PB MNC, n= 6
mice). g Proportion of AML cells entering S phase per hour in blood and BM (average ± s.e.m shown; p= 0.0003, Welch two-sample t-test; n= 3 and 6
mice)
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(Fig. 3d), but required no assumptions on death and could be
performed with a single sample harvested at a single time point.
Importantly, the method could be applied to non-exponential
growth phases, where population size changes could be a
consequence of either slower growth or cell loss, or a combination
of the two.
A constant proportion of AML cells enter S phase per hour.
The constant proportion of AML cells entering S phase per
hour in BM coupled with the slow down in the growth of AML
cell number indicated that from day 18 there was no longer
room for all progeny to remain in that organ. We reasoned
that this could explain how BM AML cell numbers grew sub-
exponentially (Fig. 1b). Therefore, we hypothesised that a sig-
nificant number of cells were displaced from the BM once most of
that space had been occupied. To test that, we measured AML cell
infiltration in PB. Consistent with our hypothesis, PB infiltration
increased dramatically during the time when AML growth in the
BM was reduced (Fig. 3e). By comparing multiple groups of mice
at different stages of BM infiltration, we identified two patterns for
the presence of AML cells in the PB where PB infiltration was low
when BM infiltration was low (<60%), and then substantially
higher when BM infiltration was high (≥60%), (Supplementary
Fig. 3).
Based on these data, the number of AML cells produced in BM
that are displaced into PB could be estimated (Methods). By day
24, these would constitute a significant proportion of the increase
in MNC counts in PB (Fig. 3f). We reasoned that if AML from
the BM was a dominant source of AML in the PB, the division
rate of PB cells could not account for expansion alone and the
proportion of AML cells entering S phase per hour in PB should
be lower. Consistent with this hypothesis, the proportion of AML
cells entering S phase per hour in PB was approximately one-
third of that in BM, at ~1% per hour (Fig. 3g).
MPPs are major cell amplifiers in steady-state haematopoiesis.
We turned our attention to early HSPCs, first examining steady-
state haematopoiesis so that we could better understand the
dynamics triggered by leukaemia growth. We acquired sufficient
numbers of three phenotypically defined primitive populations
(HSCs, ST-HSCs and MPPs) to allow reliable identification of
their BrdU+EdU−, BrdU+EdU+, BrdU−EdU+ and BrdU−EdU−
fractions (Fig. 4a). We also measured the total number of cells in
each population in the hind limbs of every mouse analysed
(Fig. 4b). As expected, HSCs were least numerous, followed by
increasingly more abundant ST-HSCs and MPPs. Knowing the
proportion of cells that entered S phase per hour (Fig. 4a) and the
number of cells in each population (Fig. 4b), we calculated the
number of cells in each population entering S phase per hour
(Fig. 4c). Of the three populations, MPPs had by far the greatest
number (left panel) and fraction (right panel) of cells entering S
phase per hour. The proportion of MPPs entering S phase is
substantially higher than that of both HSCs and ST-HSCs, which
had similar proportions of cells entering S phase. Thus, the high
number of proliferative MPPs is not solely a consequence of the
larger size of that population, and the MPP stage is a significant
amplifier of cell numbers.
CD48 level correlates with HSC proliferation and function. The
proliferation and compartment size data allowed us to directly
compare HSC and ST-HSC output with MPP cell numbers. Every
week LKS CD48−/low cells (HSCs and ST-HSCs combined) pro-
duced half as many cells as there were LKS CD48+ cells (MPPs)
(Fig. 4d). This finding was consistent with a recent study6, but did
not explain the dormancy or low proliferation rate of HSCs2–4.
In search of these more quiescent cells, we investigated the
distribution of proliferating cells (EdU−BrdU+, EdU+BrdU+ and
EdU+BrdU−) within the overall LKS compartment. We noticed
that they were particularly rare within the HSC compartment that
is most negative for CD48 (Fig. 4e). We therefore re-gated our
data based on fluorescence minus one controls to separate, on
average, the 25% LKS CD150+CD48−/low cells that had the lowest
levels of CD48. Henceforth we denote these as CD48neg HSCs,
and the remaining HSCs as CD48low HSCs (Fig. 4f). We found
that CD48neg HSCs were turning over at a substantially lower rate
than the CD48low HSCs (Fig. 4g). This was consistent with other
reports indicating that approximately 20% of LKS CD150+ CD48
−/low are label-retaining cells2 and that not all cells within that
phenotypically defined population are functional HSCs in long-
term serial transplant settings26, 29.
To investigate the functional distinction between the CD48neg
and CD48low HSCs, we tested their engraftment ability
by transplanting 100 mTomato+ cells of either type together
with 200 k whole BM haematopoietic cells from wild-type
donors into lethally irradiated recipients. The percentage of
donor derived cells was measured in the blood of CD48neg
and CD48low HSCs recipients at weeks 8, 12 and 20 post
transplant, both overall and in the B, T and Myeloid cell
compartments (Fig. 4h left panel). BM constitution at week
20 was then analysed according to BM subpopulations (Fig. 4h
right panel). Recipients of CD48neg HSCs exhibited consistently
higher engraftment at all time points in both PB and BM than
recipients of CD48low HSCs, indicating that the quiescent
CD48neg population is, indeed, functionally distinct. This result
was confirmed by a serial transplantation experiment, which
showed that only CD48neg HSCs have appreciable secondary
engraftment (Fig. 4i).
CD48neg HSCs are most resistant to ousting by AML. In con-
trast to label flux methods2–4, 24, 30, the dual label approach is
applicable to systems with evolving dynamics such as the hae-
matopoietic shutdown in the BM during leukaemic infiltration. It
has been suggested that leukaemia induces a progressive increase
of quiescence on residual haematopoietic cells, measured as
increasing proportions of cells in G012, 13. One would therefore
expect that under leukaemic stress, the proportion of primitive
haematopoietic populations entering S phase per hour would
progressively decrease. To investigate if this was the case, we
analysed the proliferation of residual healthy early HSPCs in the
MLL-AF9-driven AML model described earlier (Fig. 1).
We measured the number of CD48neg HSCs, CD48low HSCs,
ST-HSCs and MPPs entering S phase per hour (Fig. 5a). For
CD48neg HSCs, this was below the limit of detection throughout
disease progression. For CD48low HSCs and ST-HSCs, there was
no evidence of significant increase or decrease in the proportion
of cells entering S phase per hour during disease progression. For
MPPs, we found a strong linear correlation with the overall
number of MPPs remaining in the BM. This indicated that the
proportion of MPPs entering S phase per hour remained
unchanged despite their decreasing size.
To better understand how the observed proliferation dynamics
fitted with the observed cell loss, we focused on the last 6 days of
disease, when all cell populations dramatically decrease in size.
Measurement of the average cell numbers for each population
(Fig. 5b, bars) established that all cell types were reduced to
approximately 10% of their initial size (Fig. 5b, right y axis). In
numbers, the MPP compartment decreased most dramatically,
but between days 18 and 21, ST-HSCs experienced the greatest
proportional decrease and CD48− HSCs the least. Taken together,
these data raised the questions: (1) why did HSCs appear
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increasingly quiescent in previous studies12, 13; (2) could there be
a common mechanism leading to stem and progenitor cell loss
from the BM; and (3) are ST-HSCs affected by AML differently
compared to the other LKS subpopulations?
To address the first question, we focused on the relative
survival of CD48neg and CD48low HSCs, as in steady-state,
CD48neg HSCs were the least proliferative (Fig. 4g). As these cells
were being depleted at the slowest rate, we reasoned that this
could explain the previously reported increasing proportion of
quiescent HSCs12, 13. Analysis of CD150 and CD48 expression by
flow cytometry in surviving LKS cells at days 18 and 24 confirmed
the proportional enrichment of CD48neg HSCs compared with
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Fig. 4 EdU-BrdU dual pulse reveals instantaneous rate of entry into S phase of primitive haematopoietic cell populations in steady-state conditions. a
Representative FACS plot of LKS cells, showing HSC, ST-HSC and MPP populations and their relative FACS plots of EdU and BrdU incorporation patterns. b
Total number of HSCs, ST-HSCs and MPPs in BM from one hind leg. c Number (left) and proportion (right) of HSCs, ST-HSCs and MPPs entering S phase
per hour (average ± s.e.m shown; left, p= 0.252 HSC to ST-HSC, p= 0.002 HSC to MPP, p= 0.003 ST-HSC to MPP, Welch’s two-sample t-test; right, p=
0.509 HSC to ST-HSC, p= 0.004 HSC to MPP, p= 0.002 ST-HSC to MPP, Welch’s two-sample t-test; n= 15 mice analysed). d Number of cells produced
per week by HSCs and ST-HSCs compared with MPP population size based on the data presented in b and c (average ± s.e.m. shown). e Representative
FACS plot of LKS cell population, highlighting the phenotype of EdU−BrdU+, EdU+BrdU+ and EdU+BrdU− cells. f Representative FACS plot showing gates
separating HSCs with the lowest 25% expression levels of CD48 (CD48neg) and the higher 75% (CD48low). g Proportion of CD48low and CD48neg HSCs
entering S phase per hour based on EdU and BrdU uptake (average ± s.e.m shown; p= 0.019, Welch’s two-sample t-test; n= 10 mice). h Transplantation of
mTomato+ CD48neg and CD48low HSCs into lethally irradiated recipients. Left panel: time-course of engraftment at weeks 8, 12 and 20 (data, mean ± s.e.
m shown; p< 10−4 overall, B, T and Myeloid, exact one-way permutation test for mean difference between groups; n= 9 and n= 7 mice, respectively).
Right panel: bone marrow engraftment at week 20. i Secondary transplantation of mTomato+ CD48neg and CD48low HSCs into lethally irradiated
recipients. Left panel: time-course of engraftment at weeks 8, 12 and 16 (data, mean ± s.e.m shown; p< 10−4 overall, B, T and Myeloid, exact one-way
permutation test for mean difference between two groups with n= 11 mice each). Right panel: bone marrow engraftment at week 16
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LKS CD48low HSCs at the latter stages of disease (Fig. 5c). Figure
5d shows the evolution of the absolute size of the two HSC
subpopulations over time (left panel), where the substantial
depletion of CD48low HSCs in advance of CD48neg HSCs is
evident, and results in the relative enrichment of the least
proliferative HSCs (right panel).
To explain the declining cell numbers of primitive HSPCs, we
hypothesised that all haematopoietic cells may be lost indepen-
dently of cell type or proliferative state, with the only exception
being CD48neg HSCs. The sum of all MNCs (healthy and
leukaemic populations) in mice at late stages of disease was 40%
lower compared to age-matched controls (Fig. 5e). Assuming a
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densely packed BM, this suggested that malignant cells are larger,
on average, than healthy MNCs. This was confirmed qualitatively
by analysing forward scatter of healthy and malignant haemato-
poietic cells using flow cytometry (Supplementary Fig. 2), and
quantitatively by measuring cell sizes in histological sections of
BM from healthy and diseased mice. The latter data also
illustrated that the BM was equally packed with haematopoietic
cells regardless of steady-state or malignant haematopoiesis
(Fig. 5f). The estimated cell size calculated based on MNC
numbers and the measured one from histological sections were
similar, with AML cells being on average between 1.5 and 2 times
bigger than the average healthy cell, based on 1000 bootstrap
samples from two control and three AML samples at day 24
(Fig. 5g). We therefore built a simple model in which for every
new AML cell that remains in the BM, from day 18 onwards
approximately 1.5–2 non-AML cells are randomly ousted without
cell type preference. Under these circumstances, the rate of
ousting of a cell population is proportional to its size (Methods).
The resulting depletion kinetics are presented as red dashed lines
in Fig. 5b and, despite the model’s simplicity, provide a good
explanation of the data. In this model, healthy cells can be lost by
both displacement into PB or through death, and the predicted
loss of ST-HSCs remains less dramatic than observed.
To understand the interplay of displacement and death
as drivers of cell loss, we performed Annexin V and DAPI
staining on c-Kit enriched haematopoietic cells harvested
from mice at advanced stages of AML progression (Fig. 5h).
We observed a modest proportion of apoptotic and dead
HSCs and MPPs, equivalent to those observed in healthy
control mice (Supplementary Fig. 4), but detected a substantially
higher proportion of apoptotic or dead ST-HSCs when compared
with other HSPCs (Fig. 5h) and to steady-state BM (Supplemen-
tary Fig. 4). The reason why ST-HSCs were observed to be
more prone to apoptosis than other HSPC populations, especially
at high AML infiltration, remains to be elucidated. A combined
effect of death and displacement of ST-HSCs is, however,
consistent with their rate of loss being higher than that predicted
by elimination alone. The data suggested that elimination from
BM rather than cell death may be largely responsible for loss of
other HSPCs.
Discussion
Blood production is maintained by rare HSCs through pro-
liferative down-stream multipotent cell types that give rise to
lineage committed cell populations. Here, we focused on the
proliferation of early haematopoietic cells, which are responsible
for blood production maintenance, analysing their rate of entry
into S phase in steady-state and under leukaemic stress.
We determined the size of early haematopoietic cell popula-
tions in BM as leukaemia progressively infiltrates the BM. We
further developed a dual-pulse DNA labelling method that
enables in vivo measurement of the proportion of cells entering S
phase per hour in multiple cell populations simultaneously. We
analysed the malignant component of our system, based on the
well-established MLL-AF9-driven murine model of AML. Cell
number measurements revealed a decrease in AML growth in BM
towards the end of the disease. However, the dual-pulse method
established that a constant fraction of AML cells within the BM
were entering S phase per hour. Deviation from exponential
growth in cell numbers coincided with the appearance of AML
cells in the PB, where AML proliferated less vigorously, and
suggested a model where AML ultimately runs out of space in the
BM. While our data are suggestive of the ousting hypothesis,
direct confirmation would require lineage-tracing methodologies.
Interestingly, the measured proportion of cells entering S phase
per hour for BM AML cells is within the range observed with
leukaemia cells in culture49. The reduced rate of entry into S
phase of AML cells in PB compared with BM is supportive of
current hopes of improving AML outcome through the use of
mobilising agents50–52.
In steady state, we established that every week LKS CD48−/low
cells (HSCs and ST-HSCs) produced half as many cells as there
were LKS CD48+ cells (MPPs), indicating that the most primitive
cell population strongly contributes to steady-state haematopoi-
esis, in agreement with a recent study6. Interestingly, our mea-
surements of the proportion of MPP and AML cells entering S
phase per hour were not significantly different (p = 0.38, Welch’s
two-sample t-test), suggesting that mechanisms other than rapid
proliferation are at the root of aggressive expansion observed in
AML.
As there is ongoing speculation regarding the level of enrich-
ment of long-term HSCs using SLAM gating2, 3, 27–29 and a
feature of our approach is that it allows retrospective re-gating,
we investigated the proliferation of the subpopulation of LKS
CD150+CD48−/low cells identified as having the lowest CD48
expression, which we called CD48neg HSCs. These cells proved to
be less proliferative than their LKS CD150+CD48low counterpart
and thus CD48low HSCs were the more significant contributors to
steady-state blood production, consistent with a recently pub-
lished study30. CD48neg HSCs had greater reconstitution ability
than CD48low ones, in agreement with studies showing that
quiescence is linked to better engraftment ability3, 4, 8. The LKS
CD150+CD48−/low population has been fractionated based on
CD34 expression36 where CD34− HSCs have been shown to be
the most metabolically inactive3, 4. Other studies reported that
approximately 20% of LKS CD150+CD48−/low cells are label
retaining2. This figure is consistent with our work, which provides
a phenotypic identification of the least proliferative HSCs.
Overall, our data confirm that the LKS CD48+ population is a
critical haematopoietic cell number amplifier, consistent with
label retention studies2, 3. Our finding that CD48low rather than
CD48neg HSCs are more significant contributors to homoeostatic
maintenance is in line with the finding that in CD48-null mice
HSCs appear more quiescent and haematopoiesis is progressively
impaired53.
As AML cell numbers in BM grow, LKS CD150+CD48−/low
(HSCs), LKS CD150−CD48−/low (ST-HSCs) and LKS CD48+
(MPPs) numbers all decreased in concert, suggesting that a
process beyond increased HSC quiescence was responsible for
their loss. Surprisingly, we found that the fraction of MPPs that
entered S phase per hour was near constant throughout disease
progression, despite the overall reduction in the population size,
while there was no evidence of increased entry into S phase of
other HSPCs. This suggests that shut down of healthy haemato-
poiesis during leukaemia may be a consequence of a distinct
mechanism to the recently proposed one of leukaemia-induced
quiescence12, 13. Because an increase in cell death as disease
progressed was observed only for LKS CD150−CD48−/low cells
(ST-HSCs), our data led us to propose a model where cells of the
haematopoietic system are ousted from the BM by the infiltrating
leukaemia irrespectively of proliferative behaviour or phenotypic
characteristics, with the exception of LKS CD150+CD48−/low cells
with the lowest level of CD48 expression, which proved relatively
resistant to removal. As these are the least proliferative HSCs, the
data reveal a proportional enrichment of apparently quiescent
HSCs. This is consistent with earlier studies that identified G0-
enriched, engraftment-able HSCs13 that express high levels of the
quiescence inducer Egr312 were preserved despite AML cells
occupying the majority of BM. Taken together, these and our
study raise the questions of how a subpopulation of HSCs sur-
vives leukaemia growth longer than any other cell type, and
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whether indeed quiescent cells survive or, alternatively, surviving
cells are induced into quiescence.
In conclusion, we found the dual-pulse method combined with
accurate total cell counts to be essential methods for gaining novel
insights in the cellular dynamics underlying the competition
between healthy and malignant haematopoiesis. Future studies
will indicate whether similar dynamics hold true following che-
motherapy treatment, haematopoietic recovery, and disease
relapse. Understanding the reason for the differential dynamics of
HSPC subpopulations will provide clues for better targeted
interventions aimed at restoring healthy haematopoiesis in leu-
kaemia patients.
Materials and methods
Mice. All animal experiments were approved and performed according to the
standards of the animal ethics committee at Imperial College London and Sir
Francis Crick Institute, and to UK Home Office regulations (ASPA 1986). C57Bl/6
WT mice were purchased from Harlan UK Ltd., and Charles River UK; CD45.1
and mTmG mice were bred and housed at Imperial College London, UK, or
provided by the Sir Francis Crick Institute breeding facility (London, UK).
BrdU and EdU administration. For cell cycle analysis, EdU and BrdU were used.
Both are incorporated during DNA synthesis and, combined, allow analysis of cell
cycle kinetics45. Pulse-chase timings were optimised to achieve consistent in vivo
incorporation of EdU and BrdU, and later detection in the cell populations of
interest. EdU (1 mg/mouse) and BrdU (2 mg/mouse) were administered via tail
vein injection 2 h apart, unless otherwise stated; 30 min later, mice were culled and
the tissue was isolated. Poly-I-poly-C (Sigma) was administered intraperitoneally as
a single dose of 100 µg, 24 h prior to culling.
MLL-AF9 AML model. Six-week-old CD45.1 or mTmG female mice were BM
donors for the generation of AML leukaemia by retroviral transduction of purified
granulocyte/monocyte progenitors (GMPs) as previously described35 using the
pMSCV-MLL-AF9-IRES-GFP construct54. Transduction of sorted GMPs was
performed by plating sorted cells on retrovirus-coated plates in DMEM, 10% FCS,
1% non-essential amino acids, 0.1% β-mercaptoethanol, 0.5% PenStrep, 20 ng/ml
SCF, 10 ng/ml IL-3, and 10 ng/ml IL-6 for 72 h. Transduction efficiency was
determined by flow cytometry and each primary recipient mouse received 25,000
transduced cells intravenously. Primary recipients were sub-lethally irradiated (two
doses of 3 Gy greater than 3 h apart) before transplantation. Primary blasts were
harvested from the BM of primary recipients at 8–10 weeks post transplant
(infiltration >90%) and banked in liquid Nitrogen. Secondary leukaemias were set
up in non-irradiated recipients by injecting 100,000 AML blasts intravenously.
Secondary recipients were culled for flow cytometry analysis at the indicated time
points during disease development. Total MNC counts in PB were obtained by
differential cell count using an Advia 2120 haematology analyser (Siemens
Diagnostics).
Flow cytometry. All flow cytometry antibodies used are listed in Supplementary
Table 1, and all data were acquired on an LSRFortessa flow cytometer (BD BioS-
ciences, CA). For GMP and HSC subpopulations sorting, red blood cells were
lysed, then BM cells were stained with a biotin-conjugated lineage cocktail com-
prising anti-CD3, CD4, CD8, B220, Ter119, Gr1, and CD11b. Lineage positive cells
were depleted by using streptavidin-conjugated magnetic beads (Miltenyi Biotech,
Germany) and magnetic columns (LD columns/quadromacs holder, Miltenyi
Biotech). The lineage negative-enriched cells were stained with streptavidin and
antibodies against c-Kit, Sca-1, CD16/32 and CD34 before sorting for GMPs (Lin-
c-Kit+Sca-1-CD16/32+CD34hi) using a BD ARIA III.
For the analysis of the stem and progenitor cell compartments, red cell depleted
BM or PB cells were stained with the biotin-conjugated lineage antibody cocktail
and c-Kit, Sca-1, CD48, CD150 antibodies, followed by streptavidin Pacific Orange
(Life Technologies, CA).
BrdU and EdU were detected using a combination of the BrdU Kit (Becton
Dickinson) and the Click-iT EdU Kit (Life Technologies): after performing the cell
surface antigen stain, the cells were fixed and permeabilised before incubation in
the Click-iT EdU reaction. DNase treatment followed and intracellular anti-BrdU
stain was performed immediately before analysis by flow cytometry. For analysis of
BrdU/EdU incorporation in AML blasts and residual healthy haematopoietic cells,
the initial cell surface antigen staining included also anti CD45.1 antibody.
For the detection of apoptotic cells, Annexin V (APC, BB) and DAPI (Life
Technologies) staining were performed according to the manufacturers’
instructions on red cell lysed (to identify apoptotic AML cells), and red cell lysed, c-
Kit enriched BM cells (to identify apoptotic healthy cells) from healthy control and
leukaemia-burdened animals. c-Kit enrichment was performed using anti-c-Kit
magnetic beads-conjugated antibody and LD columns (Miltenyi) according to the
manufacturer’s instructions.
Calibrite beads (BD Biosciences) were used to determine the absolute cell
numbers in the populations of interest by flow cytometry. These were added to
freshly isolated, untreated BM and spleen and red cell lysed blood at a
concentration of 2–5% of the total cells in the tube and acquired by flow cytometry,
using a white blood cell/MNC gate to exclude erythrocytes from the counts
(remaining cells in BM and spleen are referred to as MNCs). Total cell numbers of
different cell populations were back calculated based on their frequency in the
samples analysed.
Measuring the proportion of cells entering S phase per hour. For a given
population of interest, let n(t) denote the number of living cells and ns(t) denote the
number of cells in S phase at time t. With es[0,t) being all cells that enter S phase
and ds[0,t) being all cells that depart S phase in the interval [0,t), then ns(t) = ns(0)
+ es[0,t) − ds[0,t). With r denoting the fraction of cells that enter S phase per unit
time, for t sufficiently small es[0,t) = rn(0)t. With a single label, BrdU, continuously
administered from time 0, the number of BrdU+ cells at time t sufficiently small
satisfies BrdU+(t) = ns(0) + es[0,t) = ns(0) + rn(0)t. Thus to extract r, one would
need measurements at two time points as one would determine the derivative of the
proportion of BrdU+ cells at t = 0, r ¼ lim
t!0 BrdU
þ tð Þ= n 0ð Þtð Þ. With two labels, EdU
administered at time 0 followed by a gap of length T to second label, BrdU, r can be
determined directly. For any T smaller than both the length of S phase and the time
to traverse G2/M/G1, one has that EdU−BrdU+(T) = es[0,T) = rn(0)T and thus, for
T sufficiently small, the fraction of cells entering S phase per unit time can be
identified as the fraction of EdU+BrdU+ cells, r = EdU−BrdU+ (T)/(n(0)T).
CD48neg and CD48low HSC transplantation. CD48neg and CD48low HSCs were
FACS sorted from the BM of mT/mG donor mice, and 100 were transplanted into
lethally irradiated WT recipients (two doses of 5.5 Gy separated by more than 3 h),
alongside 200,000 competitor WT BM cells. Baytril antibiotic was administered to
recipient mice for 5 weeks post transplant. Multi-lineage engraftment of the reci-
pients was monitored at 8, 12 and 20 weeks post transplant by FACS analysis of PB.
Whole BM was harvested from the CD48neg and CD48low HSC primary recipients.
Each experimental sample group was used to seed a secondary cohort of lethally
irradiated WT recipients, with each mouse receiving 100 pooled tomato+ HSCs
(LKS CD150+CD48−/low) and 200,000 competitor WT BM cells. Multi-lineage
engraftment was monitored as with the primary recipients.
AML cell accumulation in PB. The numbers of MNCs in blood were estimated by
measuring MNC counts per ml of blood and based on 2.5 ml total PB per mouse.
The difference in numbers between days 18 and 24 was determined by subtracting
the average from day 18 from each measurement at day 24.
Number of AML cells displaced from BM in late stage disease. The number of
AML cells produced but unaccounted for in the BM was computed by assuming
linear growth in AML BM cell numbers between days 18 and 21, where there is ~4-
fold increase, and between days 21 and 24, where the increase is ~1.9 fold. The
average proportion of EdU−BrdU+ AML cells proliferating per hour over days
18–24 was also determined, pAML = 0.03. The number of displaced cells was the
number of newly created cells in the BM less the number required to explain the
number of AML cells in the BM:
36pAML AML 18ð Þ þ 2AML 21ð Þ þ AMLð24Þð Þ  AML 24ð Þ  AML 18ð Þð Þ:
Bootstrap confidence intervals were determined by resampling the data 1000 times,
with replacement, and repeating the above computation.
Estimation of AML and healthy haematopoietic cells size. Wild-type or Col2.3-
GFP mice were lethally irradiated (two times 5.5 Gy, 3 h apart) and reconstituted
with whole BM from mT/mG donors to generate chimeras in which the size of
healthy mTomato+ BM cells could be measured. Alternatively, non-irradiated
wild-type recipients were injected with 100,000 mTomato+ GFP+ MLL-AF9 pri-
mary blasts to measure the AML cell size in histological sections. Eight weeks after
reconstitution with healthy mTomato+ BM, or at multiple stages of AML disease,
tibias and ileac bones were harvested and processed as described before16. Briefly,
the bones were fixed in periodate-lysine-paraformaldheyde (PLP), immersed in a
sucrose gradient and frozen in optimal cutting temperature (OCT) compound
(TissueTek). Sections were obtained with a cryostat (Leica) and the Cryojane tape
transfer system (Leica Microsystems) and mounted with Prolong Diamond anti-
fade (Invitrogen) for analysis. Miroscopic images were acquired with a confocal/
two photon hybrid microscope (Zeiss 780 NLO) equipped with a Mai Tai (Spec-
traPhysics) laser and 488, 561 and 633 nm lasers. The images were analysed using
ImageJ/Fiji.
Statistical analysis. Data were processed, analysed and visualised using R and
MATLAB. Statistical tests were performed as described in figure legends. The
outcomes were treated as significant if p< 0.05.
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Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request.
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